Pasteur oral cholera vaccine: studies of reactogenicity, clinical acceptability and immunogenicity in human volunteers.
Pasteur cholera vaccine consists of isolated antigenic fractions from V. cholerae El Tor Ogawa and Inaba. Enteric coated microgranules were prepared from antigen lyophilisate. Three doses of this vaccine were administered orally to 19 healthy young Thai adults at one week intervals. None of the volunteers experienced untowards reactions. The vibriocidal antibody responses manifested a significant antibody rise (> or = 4 fold) to serovar Inaba in 8 vaccinees (42.1%) and Ogawa in 4 (21.1%). Five and 6 vaccinees (26.3% and 31.6%) showed a > or = 4 fold rise of IgG and IgA anti-LPS, respectively.
Pitisuttitham
P
P
Vaccine Trial Center, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Migasena
S
S
Prayurahong
B
B
Supanaranond
W
W
Suntharasamai
P
P
Supeeranan
L
L
Chantra
A
A
Naksrisook
S
S
D000284:Administration, Oral; D000328:Adult; D000907:Antibodies, Bacterial / Q000276:immunology; D022121:Cholera Vaccines / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D006801:Humans; D008297:Male; D014734:Vibrio cholerae / Q000276:immunology
D000907:Antibodies, Bacterial; D022121:Cholera Vaccines